AEON — Aeon Biopharma Balance Sheet
0.000.00%
Last trade - 00:00- $67.09m
- $61.94m
Annual balance sheet for Aeon Biopharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|
| Period Length: | — | — | — |
| Source: | PROSPECTUS | PROSPECTUS | 10-K |
| Standards: | USG | USG | USG |
| Status: | Final | Final | Final |
| Cash | |||
| Cash and Short Term Investments | 5.13 | 9.75 | 5.16 |
| Prepaid Expenses | |||
| Total Current Assets | 5.15 | 9.84 | 6.22 |
| Gross Property, Plant And Equipment | |||
| Accumulated Depreciation | |||
| Net Property, Plant And Equipment | 0.922 | 0.906 | 0.594 |
| Other Long Term Assets | |||
| Total Assets | 6.44 | 10.8 | 6.84 |
| Accounts Payable | |||
| Accrued Expenses | |||
| Notes Payable / Short Term Debt | |||
| Current Portion of Long Term Debt / Capital Leases | |||
| Total Other Current Liabilities | |||
| Total Current Liabilities | 20.8 | 82.6 | 13 |
| Long Term Debt | |||
| Total Long Term Debt | |||
| Total Debt | |||
| Minority Interest | |||
| Total Other Liabilities | |||
| Total Liabilities | 103 | 160 | 160 |
| Redeemable Preferred Stock | |||
| Common Stock | |||
| Additional Paid In Capital | |||
| Retained Earnings (Accumulated Deficit) | |||
| Treasury Stock | |||
| Other Equity | |||
| Total Equity | -97 | -150 | -153 |
| Total Liabilities & Shareholders' Equity | 6.44 | 10.8 | 6.84 |
| Total Common Shares Outstanding |